📰 Technologies Associ News

Technologies Associ News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Technologies Associ. Real-time updates on events, politics, business and more.

Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia

December 11, 2023

PRINCETON, N.J.--(BUSINESS WIRE)--Dec 10, 2023--

United States Franck Morschhauser Bristol Myers Squibbmedia Bristol Myers Squibb Anne Kerber Tanya Siddiqi

Source: eagletribune.com

Liso-Cel Produces Deep, Durable Responses in Patients with Hard-to-Treat Lymphomas

June 22, 2023

Treatment with lisocabtagene maraleucel led to strong and durable response rates with little serious adverse effects in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma.

United States Michael Wong Bristol Meyers Squibb Franck Morschhauser Department Of Lymphoma Hematology At Centre Hospitalier Universitaire De Lille

Source: pharmacytimes.com

Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023

June 17, 2023

In TRANSCEND FL, 97% of patients with relapsed or refractory follicular lymphoma treated with Breyanzi achieved a response, with 94% achieving a complete response, and 81.9% of responders in ongoing... | June 17, 2023

United States Bristol Myers Squibb Anne Kerber Michael Wang Franck Morschhauser Cell Therapy Development

Source: marketscreener.com

Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023 | Business

June 17, 2023

PRINCETON, N.J.--(BUSINESS WIRE)--Jun 17, 2023--

United States Anne Kerber Franck Morschhauser Bristol Myers Squibb Michael Wang Drug Administration

Source: maryvilleforum.com

Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023 | National Business

June 17, 2023

PRINCETON, N.J.--(BUSINESS WIRE)--Jun 17, 2023--

United States Anne Kerber Franck Morschhauser Bristol Myers Squibb Michael Wang Cell Therapy Development

Source: joplinglobe.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Technologies Associ News Today

Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia

Liso-Cel Produces Deep, Durable Responses in Patients with Hard-to-Treat Lymphomas

Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023

Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023 | Business

Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023 | National Business

Stay Updated with Latest News

Explore More Categories